Abiopharma

🔍 Sijbrandij Sytse (Director)

Company: Gitlab Inc. (GTLB)

Report Date: 2026-04-15

Detailed Transactions and Holdings:

• Acquired 116,200 shares of Class A Common Stock (Direct)
  Date: 2026-04-15 | Code: C | equity_swap_involved: 0 | shares_owned_after: 116,200.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 116,200 shares of Class A Common Stock at $20.77 per share (Direct)
  Date: 2026-04-15 | Code: S | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F3, F4, F2
• Sold 116,200 shares of Class B Common Stock (Derivative)
  Date: 2026-04-15 | Code: C | equity_swap_involved: 0 | shares_owned_after: 15,134,451.00 | transaction_form_type: 4 | Footnotes: F1, F1, F1, F1, F2

Footnotes:

• F1: Each share of the Issuer's Class B common stock (the "Class B Stock") is convertible into one share of the Issuer's Class A common stock at any time and will convert automatically upon certain transfers and upon the earlier of (i) ten years from the date of the Issuer's initial public offering ("IPO"), (ii) the death or disability of the Reporting Person, (iii) the first date following the completion of the IPO on which the number of shares of outstanding Class B Stock (including shares of Class B Stock subject to outstanding stock options) is less than 5% of the aggregate number of shares of the Issuer's common stock then outstanding and (iv) the date specified by a vote of the holders of two-thirds of the then outstanding shares of Class B Stock.
• F2: These securities are held by the Sytse Sijbrandij Revocable Trust dated February 21, 2019, of which the Reporting Person is the sole trustee.
• F3: This transaction was executed pursuant to a trading plan entered into by the reporting person, as the sole trustee of the Sytse Sijbrandij Revocable Trust dated February 21, 2019, on December 19, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
• F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.46 to $20.99, inclusive. The Reporting Person undertakes to provide to GitLab Inc., any security holder of GitLab Inc., or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote 4.